Thermo Fisher Scientific Ustekinumab Monoclonal Antibody (9A5)

Applications

• ELISA (ELISA)
  Tested Dilution: 0.05–1 µg/mL

Product Specifications

Product Specific Information

Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
The lyophilized product remains stable up to 1 year at -20°C from date of receipt. Upon reconstitution, it can be stored for 2–3 weeks at 2–8°C or for up to 12 months at -20°C or below. Avoid repeated freezing and thawing cycles.

Target Information

Ustekinumab is a human immunoglobulin (IgG1 kappa) monoclonal antibody directed against interleukin (IL)-12 and IL-23, cytokines involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig transgenic mice.
Ustekinumab acts as a targeted biologic disease-modifying anti-rheumatic drug (bDMARD), used in the management of inflammatory conditions involving IL-12 and IL-23 signaling pathways. IL-12 and IL-23 are heterodimeric cytokines that trigger immune responses such as natural killer cell activation and CD4+ T-cell differentiation.
These cytokines are implicated in chronic inflammatory diseases, including psoriasis and inflammatory bowel disease. They modulate lymphocyte functions, including Th1 and Th17 subsets, which activate downstream pro-inflammatory mediators such as TNFα and IFNγ, driving innate and adaptive immunity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.